FIGURE 2.

(a) Relapse‐free survival (R‐FS) following autologous haematopoietic stem cell transplantation (AHSCT; red) and treatment with cyclophosphamide (Cy; blue) during the treatment epoch was higher in AHSCT compared to Cy patients: 100% versus 55% at Year 3, respectively, p < 0.0001. (b) R‐FS over the whole follow‐up period following treatment start was higher in the AHSCT group compared to the Cy group: 100% and 52% at Year 5, respectively (p < 0.0001). The number of patients in observation at each timepoint is reported below the corresponding chart. (c) Annualized relapse rate (ARR) over 2 years prior to treatment start (blue) and during the first 2 years of treatment (red) in the AHSCT (right panel) and Cy (left panel) groups. ARR dropped in both groups (p < 0.0001) following treatment start. Pretreatment ARR did not differ between the two groups (p = 0.574), but ARR on treatment was lower in the AHSCT group compared to the Cy group (p < 0.001), suggesting that only AHSCT was able to induce the complete suppression of new inflammatory activity [Colour figure can be viewed at wileyonlinelibrary.com]